DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DongKoo Bio & Pharma Co Ltd
Net Income (Common)
DongKoo Bio & Pharma Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
|
Net Income (Common)
₩770.3m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩191.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
₩267B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩169.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
70%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Net Income (Common)
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
DongKoo Bio & Pharma Co Ltd
Glance View
DongKoo Bio & Pharm Co. Ltd. operates as a holding company engaged in the manufacture and sale of pharmaceutical products and health supplements. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-02-13. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The firm is involved in contract manufacturing organization business. The company manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The firm distributes its products within the domestic market and to overseas markets, including America and Europe.
See Also
What is DongKoo Bio & Pharma Co Ltd's Net Income (Common)?
Net Income (Common)
770.3m
KRW
Based on the financial report for Sep 30, 2025, DongKoo Bio & Pharma Co Ltd's Net Income (Common) amounts to 770.3m KRW.
What is DongKoo Bio & Pharma Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-48%
Over the last year, the Net Income (Common) growth was -95%. The average annual Net Income (Common) growth rates for DongKoo Bio & Pharma Co Ltd have been -55% over the past three years , -48% over the past five years .
